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Abstract
Many randomized trials evaluate an intervention effect on time-to-event outcomes.
Individual participant data (IPD) from such trials can be obtained and combined in a
so-called IPD meta-analysis (IPD-MA), to summarize the overall intervention effect.
We performed a narrative literature review to provide an overview of methods for
conducting an IPD-MA of randomized intervention studies with a time-to-event out-
come. We focused on identifying good methodological practice for modeling frailty
of trial participants across trials, modeling heterogeneity of intervention effects,
choosing appropriate association measures, dealing with (trial differences in) censor-
ing and follow-up times, and addressing time-varying intervention effects and effect
modification (interactions).
We discuss how to achieve this using parametric and semi-parametric methods,
and describe how to implement these in a one-stage or two-stage IPD-MA frame-
work. We recommend exploring heterogeneity of the effect(s) through interaction
and non-linear effects. Random effects should be applied to account for residual het-
erogeneity of the intervention effect. We provide further recommendations, many of
which specific to IPD-MA of time-to-event data from randomized trials examining
an intervention effect.
We illustrate several key methods in a real IPD-MA, where IPD of 1225 partici-
pants from 5 randomized clinical trials were combined to compare the effects of
Carbamazepine and Valproate on the incidence of epileptic seizures.
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1 INTRODUCTION
Relative intervention effects (e.g. hazard ratios) are most reliably evaluated in randomized clinical trials (RCT). However, multi-
ple RCTs of the same intervention may provide inconclusive or conflicting evidence on efficacy or safety. Discrepancies between
evidence from different RCTs may arise due to chance, or in particular due to heterogeneity in the true intervention effect. This
heterogeneity is commonly caused by across-trial differences in, for example, study design (e.g. recruitment strategy, length of
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follow-up, or analysis methods), case-mix of participants, definition of the studied outcome(s), the implementation (e.g. dosage
or intensity) of the intervention. This motivates the need to systematically integrate and summarize evidence across trials, to
facilitate evidence-based-medicine.
This can be achieved using a systematic review with meta-analysis (MA). Whereas most meta-analyses are based on
aggregated data (AD) from available literature, individual participant (or patient) data meta-analyses (IPD-MA) of multiple
intervention studies are considered the gold standard.1,2,3 IPD-MA offers several advantages, as the meta-analyst has full con-
trol of the data analysis and uses the data at the individual participant level.4 Key advantages are the standardisation of outcome
and follow-up definitions, checking of data and quality, proper modelling of time-to-event outcomes, and the exploration of
intervention-covariate interactions at the participant level.4,5 It may thus come to no surprise that IPD-MA are increasingly
common.6,7
Extensive guidance has previously been provided for conducting an IPD-MA of intervention effects, for various types of
outcome data, such as binary,8,7,9 continuous,6,7,10,11 ordinal7 and count outcomes.7 Yet, IPD-MA are especially useful when
analyzing time-to-event outcomes in intervention studies, as censored outcomes can be reassessed for the meta-analysis, survival
measures (e.g. hazard ratios, median survival) can be calculated directly and independent to trial reporting, follow-up length can
often be increased, time-varying hazard ratios can be examined, and effect modifiers (intervention-covariate interactions) can
be assessed.12,13
Whereas a wealth of methods have been developed for analyzing and predicting time-to-event outcomes in single stud-
ies,14,15,16,17 limited guidance exists on their application in IPD-MA settings. In this article, we aim to provide readers with this
guidance, by means of our systematic search of databases, narrative review and explanation, and an applied example. Although
we focus IPD-MA of trials, the methods we describe are also applicable to multi-center trials.
In the next section, we provide the principles as well as several major issues of time-to-event analyses, that are common in
not only IPD-MA but also in single studies. In section 3 we provide details of our systematic literature search of methodology
for IPD-MA of time-to-event outcomes, and then a narrative review thereof follows in section 4 where we discuss the one- and
two-stage approaches to meta-analysis, and in section 5 where we discuss issues in more detail. Then, in section 6 we apply
several key methods of the review to a real IPD meta-analysis of clinical trials. Finally, we give provide a discussion in section
7 and concluding remarks in section 8.
2 PRINCIPLES OF TIME-TO-EVENT ANALYSIS
The analysis of trials with a survival outcome (e.g. death) typically involves statistical models that account for the time 𝑇surv,𝑖
elapsed until subject 𝑖, 𝑖 = 1, .., 𝑛 developed the event of interest. We here denote the probability for subject 𝑖 to remain event-
free for at least 𝑡 time by the survival function 𝑆(𝑡) = 𝑃𝑟(𝑇surv,𝑖 > 𝑡). A key challenge in time-to-event (TTE) data is that for
many participants 𝑇surv,𝑖 is censored to 𝑇cens,𝑖, for instance due to dropout or the end of the study. This implies that for those
participants 𝑇surv,𝑖 > 𝑇cens,𝑖. Hence, the outcome for subject 𝑖 is typically summarized by the observed event-free or survival time
𝑇𝑖 = min(𝑇surv,𝑖, 𝑇cens,𝑖) and the event status𝐷𝑖 (where𝐷 = 0 when censored, and𝐷 = 1 when the event of interest was observed
to have occured). We can compare the survival times of intervention groups and control, while accounting for censoring, with
a variety of regression methods.
A commonly used method for analyzing right-censored TTE data is the Cox proportional hazards (PH) model.18 In this semi-
parametric model the effect of the covariates is modeled parametrically, whereas the baseline is left unspecified. It is typically
assumed that the ratio of the hazards for any two individuals is constant, irrespective of 𝑡. The hazard ℎ(𝑡|𝑿) for an individual
with covariate vector 𝑿′ = (𝑋1,… , 𝑋𝑘) is given by equation 1.1 (Table 1), where 𝜷𝑻 = (𝛽1, ..., 𝛽𝑘) is a vector of regression
parameters. The function ℎ0(𝑡) represents the baseline hazard, which is left unspecified.14,15 The hazard ratio for two individuals
𝑖 = 1, 2 is then given by exp{𝜷′(𝑿1 −𝑿2)}. For the analysis of randomized trials, 𝑿 typically just contains a single covariate
representing the intervention indicator (e.g. 𝑋𝑖 = 0 for subjects in the control arm and 𝑋𝑖 = 1 for subjects in the intervention
arm) such that exp (𝛽) can directly be interpreted as the relative intervention effect.
An important consideration is whether to include other (prognostic) covariates in the Cox PH model alongside treatment. In
many time-to-event models, including the Cox PH model, the observed unadjusted intervention effect of a protective intervention
may change over time due to covariates (i.e. frailty), even if these covariates are perfectly balanced between the intervention
groups.19,20 Frail participants will have a higher incidence rate than less frail participants. If the intervention is protective,
frail participants in the intervention group will have a lower incidence rate than frail participants in a control (or an ineffective
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intervention) group and participants that are not frail. Over time, the proportion in the control group that is still at risk will
increasingly consist of participants that are not frail, whereas this will take longer for the intervention group, thereby resulting
in an imbalance in frailty. For trials with a high event rate and most frailty distributions, the unadjusted intervention effect will
attenuate towards the null (hazard ratio of 1) as time progresses, which violates the proportional hazards assumption.21 The
unadjusted intervention effect is then the marginal intervention effect,22 i.e. the average intervention effect for the population as
a whole, averaged across all time-points. Hence, it is dependent on the length of the follow-up.
If the intention is to measure a conditional intervention effect, i.e. the intervention effect for a participant with given covariate
values, the observed unadjusted intervention effect is often not valid. Instead, covariates should be included in the model, to
obtain a conditional intervention effect.23,24 Further, the adjustment for a prognostic covariate often increases the power for
finding an intervention effect.25 Alternatively, an AFT model could be used (sections 5.1 and 5.2), for which the effect of missing
covariates is absorbed into the baseline parameters, leaving the unadjusted intervention effect unaffected.21
The Cox PH model has numerous appealing properties, in particular allowing the estimation of hazard ratios for included
covariates without requiring the shape of the baseline hazard to be specified. However, its implementation is not always justified.
For instance, difficulties may arise when hazards are non-proportional. Although effects to model non-PH can be included (e.g.
with splines, interactions or time-varying effects) in a Cox PH model, this usually complicates the interpretation of the estimated
intervention effect. For these reasons it is often recommended to adopt a model where proportionality occurs on another scale
when proportionality of hazards is violated, which is discussed in section 5.2. When absolute survival probabilities for individual
participants are of primary interest, it can be useful to define a parametric function for ℎ0(𝑡), and thus to abandon Cox PH models
altogether,26,27 which is discussed in section 5.1. Indeed, even when the focus is mainly on an intervention effect, translation of its
hazard ratio to the absolute risk scale is important, which requires the baseline survival to be modelled, either parametrically or
non-parametrically. For a full overview of R packages on time-to-event analysis, see cran.r-project.org/web/views/Survival.html.
3 IPD META-ANALYSIS METHODS: REVIEW
Increasingly often, IPD from multiple studies are available for analysis. This introduces new challenges and allows for different
approaches for analysis, which we set out to identify. We conducted a literature review to identify scientific articles concerning
statistical methods for IPD-MA of time-to-event data.
3.1 Methods
We systematically searched through Pubmed and Web of Science using the search filters supplied in Supporting Information
1, from conception until December 31st, 2018. In addition, we added suggestions and performed cross-reference checks of the
obtained articles. Articles were considered eligible for inclusion if they described statistical methods for analyzing multiple or
clustered individual participant data sets with a time-to-event outcome. Publications that met at least one of the following criteria
were excluded from our review:
• Full text of the manuscript not available,
• Not published in English,
• Not a peer reviewed article,
• Application of methods without methodological focus,
• No focus on at least one of the following topics:
- time-to-event outcomes,
- IPD,
- estimation of intervention effects,
- meta-analysis or analysis of clustered data.
3.2 Results
A total of 1887 unique records were identified through our search strategy, and were deemed eligible for title and abstract
screening (Figure 1). Of these, 1713 were removed during screening because the titles did not have a methodological focus. The
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FIGURE 1 Flowchart of inclusion and exclusion of papers for review.
remaining 174 records were assessed on the full-text, of which 58 met the inclusion criteria and 116 did not. Further, a total
of 159 unique records were assessed after being suggested or found through cross-referencing. Of these, 16 suggestions and 54
cross-references met the inclusion criteria and were included in the review. A total of 128 articles were included in the review,
of which a complete list can be found in Supporting Information 3.
The core methods for analyzing TTE outcomes in IPD-MA are described in section 4. The structure of this section was
defined independent of the review, yet the description of methods therein has resulted from the review. Further, extensions to
these methods, such as relaxing the proportionality of hazards assumption, modeling multiple interventions or outcomes, and
methods for missing data are described in section 5.1, which was grouped according to the topics identified in the review. The
review has resulted in ten key recommendations backed by references, which are summarized in Table 2.
4 DESCRIPTION OF METHODS
4.1 Time-to-event analysis in individual participant data meta-analysis
When IPD from multiple trials are available, summary estimates for relative intervention effects can be obtained using the
so-called one-stage or two-stage approaches.28 In the conceptually simpler two-stage approach (section 4.2), the IPD from
each trial is analyzed separately to produce trial-specific estimates of relative intervention effect (e.g. hazard ratios), using the
same methodology in each trial (e.g. Cox regression). In the second stage, estimates of intervention effect are combined into a
weighted average using traditional meta-analysis methods that ideally account for possible between-trial heterogeneity. In the
one-stage approach (section 4.3), data from all studies are analyzed in one analysis, and a variety of methods can be used to
account for clustering of participants within studies.16,29,14,30,7 In both the one- and two-stage approaches, methods to account
for heterogeneity in intervention effects across studies are available (Table 3).1,30,7 In the one-stage approach, one must also
decide how to model or account for heterogeneity in other parameters (such as adjustment factors or terms defining the baseline
hazard). For a discussion on the choice between the one-stage and two-stage approaches see section 8.
4.2 Two-stage approach
The two-stage approach is often considered the most convenient approach for IPD meta-analysis, as it does not necessarily require
IPD to be exchanged. For instance, each trial can be analyzed separately, and only their summary statistics are combined. The
approach is particularly appealing when not all trials provide IPD, as it allows reported intervention effects and their respective
standard errors from non-IPD trials to be analyzed in the second stage, together with the estimates from the IPD trials.
In the first stage, common methods for TTE analysis can be used to obtain estimates of relative intervention effect for each trial
(so-called aggregate data). For instance, when applying Cox regression (equation 1.1), this yields the log hazard ratio estimates
𝛽𝑗 and their corresponding error variance 𝑉 (𝛽𝑗), for trial 𝑗 = 1, ..., 𝐽 . Afterwards, the estimated intervention effects can be
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summarized by calculating a weighted average. For instance, in a so-called common (or fixed) effect meta-analysis it is assumed















where 𝑉 is the variance. Hereby, it is assumed that the within-trial variances 𝑉 (𝛽𝑗) are known (i.e. estimated without
uncertainty). The common effect meta-analysis model can also be formulated as follows:
𝛽𝑗 ∼  (𝛽IV, 𝑉 (𝛽𝑗)) (2)
If certain trials provide no IPD, but the intervention effect and its variance are available in the literature, these can be included
in the second stage of the two-stage framework,31 provided that the models in the first stage are specified the same. If a trial has
a small sample size, the Maximum Likelihood estimator of the intervention effect can be affected by small sample bias.32 Worse
still, if considerable censoring is present, the likelihood may be monotone and the Maximum Likelihood may be inestimable,
depending on the intervention and covariate distributions.33 This can be resolved by applying Firth’s correction to the likelihood
in the first stage,32,33 or by opting for a one-stage model instead.
The assumption that an intervention effect is common across trials is often unrealistic, as trials are often affected by
between-trial heterogeneity.34,35 This heterogeneity may, for instance, appear when participant-level covariates interact with the
intervention effect (i.e. effect modification), when small sample bias is present in some estimates of the intervention effect, or
when aggregate data are based on invalid modeling assumptions (e.g. in the presence of non-proportional hazards, non-PH). For
time-to-event analysis, between-trial heterogeneity may also arise due to selection effects. In particular, participants who are
more frail and therefore more susceptible to the outcome, are no longer at risk after having an event. Therefore, over time, the
most frail participants are removed from the risk set, whereas the less frail participants remain at risk (see section 2).19,23,36,14
This, in turn, may lead to different intervention effects across trials if the follow-up length differs across trials. For these rea-
sons, in the two-stage approach it is generally recommended to adopt a random effects meta-analysis model, which is typically
specified as:
𝛽𝑗 ∼  (𝛽𝑗 , 𝑉 (𝛽𝑗))
𝛽𝑗 ∼  (𝛽RE, 𝜏2) (3)
In contrast to common effect models, random effects models allow for differences in 𝛽𝑗 due to sampling error within studies
(reflected by 𝑉 (𝛽𝑗)) and due to heterogeneity in the true intervention effects 𝛽𝑗 across studies (reflected by 𝜏2). Estimates for 𝛽RE
can thus be interpreted as the average intervention effect across studies. A confidence interval for 𝛽RE is traditionally constructed
as 𝛽RE ± 𝑧1−𝛼∕2
√
𝑉 (𝛽RE), where 𝑧1−𝛼∕2 is the upper 𝛼∕2 quantile of the standard normal distribution.37 To account for the
uncertainty in 𝜏2 and thereby improve the coverage of the interval, the Hartung-Knapp approach to confidence intervals is given
by 𝛽RE ± 𝑡𝐽−1,1−𝛼∕2
√
𝑉HK(𝛽RE), where 𝑡𝐽−1,1−𝛼∕2 is the upper 𝛼∕2 quantile of a 𝑡-distribution with 𝐽 − 1 degrees of freedom,
and 𝑉HK(𝛽RE) is a modified variance estimate.38,39,40,41,42
4.2.1 Heterogeneity of the intervention effect in the two-stage approach
Statistical heterogeneity in the intervention effect can be recognized by 𝜏 > 0. The influence of heterogeneity on intervention
effects may be explored by constructing a prediction interval, which estimates the interval of the likely intervention effect in a
(new) individual trial and can be calculated approximately as follows43,44:
𝛽RE ± 𝑡𝐽−𝑘,1−𝛼∕2
√
𝜏2 + 𝑉 (𝛽RE), (4)
where 𝛽RE is an estimate of 𝛽RE and 𝑉 (𝛽RE) its variance. Typically the 𝑡𝐽−2,1−𝛼∕2 quantile is used here, although similar to
the confidence interval there is no consensus on the distribution and its degrees of freedom.43,44 When random effects models
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indicate the presence of important statistical heterogeneity (i.e. 𝜏 > 0, or a wide prediction interval) of the intervention effect,
the interpretation of the overall summary estimate, 𝛽RE, may become difficult or meaningless. Therefore, it is often helpful to
identify sources of heterogeneity in intervention effect (see Table 4).12 This can, for instance, be achieved by assessing the
relation between relevant trial-level covariates (e.g. level of blinding, or dosage) and the trial effect estimates, also known as
meta-regression.45
When patient-level associations with treatment effect are of interest, it is better to model interactions between participant-
level characteristics (e.g. participant age) on the participant level. In the two-stage approach, the statistical interaction between
the relevant covariate and intervention are first estimated separately in each trial, and then the resulting coefficients are meta-
analyzed using traditional meta-analysis models.34,46 When the intervention effect changes over time, differences in follow-up
time between trials will lead to heterogeneous estimates of intervention effect across trials, if unaccounted for. This heterogeneity
of intervention effects can be quantified with random-effects meta-analysis, but would preferably be modeled directly (section
5.2).
4.2.2 Estimation
A commonly used approach to estimate the heterogeneity from the random effects model (equation 3), is to use the method
of moments by DerSimonian and Laird (DL).47 This estimator is biased downwards when the true heterogeneity is moderate
or high and sample sizes are low, as the variance estimates are assumed to be known and fixed,48 leading many researchers to
suggest alternatives, the most important of which are mentioned here. The two-step Paule-Mandel method is similar to DL, but
iteratively estimates the study weights, and has reduced bias for high values of 𝜏. Another alternative is the Maximum Likelihood
(ML) estimator. Although the MSE of the ML estimator for 𝜏 is small, it is very biased when 𝜏 is large and the included studies
are small.49 The Restricted Maximum Likelihood (REML) estimator yields less biased estimates of 𝜏 and has relatively low
MSE.50,51,52 Therefore, REML and the two-step Paule-Mandel method are the recommended estimators for 𝜏.48,52
As there may be considerable uncertainty in the heterogeneity estimate regardless of which estimator is used,52 it is recom-
mended to report a confidence interval for the heterogeneity as well.53 This may be estimated with the Q-profile method41,54
or the generalised Cochran between-study variance method.49 Further, it should be noted that when fewer than 10 trials are
included in the meta-analysis, or when trials are small or the outcome rare, no currently available method can reliably estimate
the heterogeneity.52
Even though estimates for heterogeneity in meta-analysis tend to be biased in many situations, this barely biases the summary
effect estimate, unless there are very few events.52 The confidence intervals of the summary effect can be constructed by applying
the Hartung-Knapp-Sidik-Jonkman HKSJ method for confidence intervals,55,56 which had good coverage in simulations for a
minimum of two studies, unless the number of events was very low.57,52 This may be corrected by applying a modification
that ensures that the confidence intervals are at least as wide as a fixed-effects meta-analysis confidence interval.52 Hence, it is
currently recommended to apply a random effects model estimated with REML or two-step Paule-Mandel, and to use the HKSJ
method for confidence intervals.52 Alternatively, Bayesian random-effects models may be used. However, in the simulation
studies discussed here either aggregate data or non time-to-event IPD were generated, which is a concern considering that it has
been suggested that the performance of the estimators may be related to the type of outcome.49 For a comprehensive overview
of meta-analysis estimators see58,49,59, for a comparison of their performance see48,52, for an overview of software see49 as well
as the two recent packages admetan and ipdmetan,60 and for an up-to-date overview of R packages see cran.r-project.org/web/
views/MetaAnalysis.html.
4.3 One-stage approach
4.3.1 Accounting for clustering
When applying the one-stage approach, within-trial and between-trial relationships are estimated simultaneously, which can
give a more complete understanding of the data.13 As is the case for two-stage meta-analysis, a one-stage meta-analysis must
account for clustering (Table 3).29,30 Participants in different studies may differ on unmeasured covariates, which will lead to a
biased estimate of the conditional (i.e. for a participant with given covariate values) intervention effect regardless of balance of
these covariates between intervention groups, if not adjusted for (section 2).20 Whereas the two-stage approach naturally deals
with this by estimating separate baseline hazards for the different studies, in the one-stage approach we can use stratification
(section 4.3.2), frailty models (section 4.3.3) or marginal models (section 4.3.4).
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4.3.2 Stratified models
A commonly used approach is to apply a Cox model with stratified baseline hazards but a common intervention effect (equation
5.1, Table 5).12,61,16,62 This allows the shapes of the baseline hazards to vary between trials, whereas the hazards of the different
intervention groups are assumed to be proportional within trials, and gives a single estimate of overall intervention effect. When
the sample sizes per trial are very small and many trials are included, the stratification of baselines is less efficient than the use
of frailty terms,16 though it also requires fewer assumptions as it fully accounts for any differences in baselines between trials.
For the meta-analysis of trials that are each powered to detect a clinically significant intervention effect this should not be an
issue, thereby making the stratification of the baseline the preferred model specification.
4.3.3 Frailty models
Rather than stratifying the baseline hazard across the trials, it is possible to model their distribution through frailty terms. A
frailty term is a random parameter (i.e. random intercept) within the baseline hazard function that is assumed to follow a specified
distribution and thereby allows for differences in baseline rate between (groups of) participants that are a result of unmeasured
covariates. Shared frailty models (equation 5.2, table 5) are designed to account for these differences in unmeasured covariates
between trials. Therefore, the assumption in a frailty model is that the baseline hazards in each study have the same shape but
a different magnitude. The estimated intervention effect is then to be interpreted relative to other participants in the same trial
with the same frailty and covariates. If the baseline hazard of this model is left unspecified, this leads to the Cox PH model with
random trial intercept.12,14 When data from multiple multi-center studies are combined, nested frailty models can be applied.63
It is common to assume a gamma distribution for the frailty, for mathematical or computational reasons,24,14 or a normal
distribution for the log-frailty, as this bears similarity to the generalized linear mixed effects model,14,64 though many other
distributions including the inverse Gaussian, positive stable, and compound Poisson are possible.16,14,17 Previous studies have
demonstrated that the gamma frailty model appears to be fairly robust against misspecification of the frailty distribution,65,66
that it describes the frailty of survivors for a large class of hazard models,24 and that it can have more power than a stratified
model.67,16,66 Therefore, frailty models are generally recommended when the number of participants per trial is very low. Yet,
when the number of participants per trial is large, as is often the case in meta-analysis when individual trials are designed to
have sufficient power to test for an intervention effect, the frailty and stratification approaches will usually yield similar results,
given that the assumptions are met.
When a frailty is applied to the baseline hazard, the median hazard ratio (MHR) can be used to evaluate the meaning of this
frailty in the context of the different studies.68,69,70 The MHR is the median relative difference in the hazard of the occurrence of
the outcome when comparing identical participants from two randomly selected studies ordered by hazard. When a log-normal
distribution is assumed for the frailty, the Median Hazard Ratio (MHR) can be computed as exp{
√
2𝜎2Φ−1(0.75)}, where Φ−1
is the inverse of the standard normal distribution.69,70
4.3.4 Marginal models
In the analysis of clustered data, such as IPD from different studies, where the interest lies in the average intervention effect for
the target population as a whole, we may use marginal models. In such models the dependence between participants from the
same trial is not modeled explicitly but standard errors are adjusted for it.71,72 Intervention effects are interpreted as relative to
participants drawn randomly from the entire target population from which the participants are considered to be sampled.73 When
the interest lies in the intervention effect of participants in the individual studies or in the causes of heterogeneity of intervention
effects across studies or subgroups, as in an IPD-MA often is the case, conditional models are needed.74
4.3.5 Estimation
Maximum Likelihood (ML) estimates of the mixed effects Cox model may be obtained with a Newton-Raphson proce-
dure,75 with penalization methods by constraining the frailty terms with a penalty,76,77,78 by expectation-maximisation,79 or by
expectation-maximisation and penalization.80
Further, residual maximum likelihood (REML) estimates of the mixed effects Cox model can be obtained with a Newton-
Raphson procedure,75,12,13 or with penalization methods by constraining the frailty terms with a penalty.76,77 As the penalized
method does not take uncertainty of 𝜏2 into account, it has been suggested that it produces less precise estimates of the
intervention effect.62 However, comparative evidence is currently lacking.
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Alternatively, the mixed effects Cox model can be estimated with a poisson model,81 where the time-scale is split into intervals
defined by event times.82 Mixed effects parametric models can be estimated with Maximum Likelihood by adaptive Gauss-
Hermite quadrature.83 Mixed effects Weibull models can also be estimated with REML.81
The Bayesian framework allows for the estimation of a wide range of time-to-event models. For instance, the Cox random
effects model can be estimated using Bayesian methods.84,85,16 A random trial effect and an intervention by trial interaction
may be evaluated simultaneously in a Bayesian Cox PH model.86 For a discussion of commensurate priors for incorporating
between-trial variability in a Bayesian meta-analysis, see87. Finally, an overview of software for the estimation of one-stage
time-to-event models is given in Table 6.
4.3.6 Heterogeneity of the intervention effect in the one-stage approach
Similar to the two-stage approach, we may expect heterogeneity of the intervention effect in the one-stage approach, which makes
the common effects assumption untenable. As such, it is also recommended for one-stage models to assume random effects
(equation 5.3, Table 5),79 and to investigate the causes of this heterogeneity, if present.12 One possible cause of heterogeneity
of the intervention effect is effect modification (i.e. interaction) at the individual-level, which can be investigated by adding an
interaction term in the one-stage model.29 Crucially, when including such an interaction term (e.g. an intervention-covariate
interaction) in the one-stage approach, special care must be taken to avoid the amalgamation of within- and across-trial informa-
tion, as this may lead to ecological bias. This can be achieved by centering the covariates by their mean values within trials, such
that the interaction estimate is then only based on within-trial information.88 To improve the estimation of between-study vari-
ance and the coverage of confidence intervals, the intervention variable can be centered within studies as well. To further prevent
the borrowing of information across studies that may affect the estimate of the intervention effect in the one-stage approach, a
covariate by trial indicator interaction can be included. This stratifies the covariates effects as it allows covariate effects to be
estimated separately for each study (see Table 3).
When there are differences in follow-up time between trials and the intervention effect changes over time, the estimated
intervention effects (as quantified by random effects) will be different per trial. If this is unaccounted for, this will lead to
heterogeneity of the intervention effect. This can then be investigated by modeling the effect as time-dependent (section 5.2).
In the two-stage approach the influence of trial-level characteristics on the intervention effect can be estimated with meta-
regression in the second stage. In the one-stage approach it is possible to simultaneously estimate the heterogeneity of baseline
rate of the participants within different studies, the heterogeneity of intervention effects and their correlation.78
5 EXTENSIONS
5.1 Modeling the baseline hazard function
Whereas the Cox PH model leaves the baseline hazard unspecified, we may apply a parametric model by specifying a baseline
hazard (Table 1), either in the first stage of the two-stage approach, or within the one-stage approach. To allow for flexible
shapes of the baseline hazard, we can apply spline functions. Particularly the approach of Royston and Parmar is useful, where
the baseline cumulative hazard is modelled using restricted cubic splines,89 and which has been extended to allow for random
effects.83
Parametric models are especially suitable when absolute (rather than relative) risks for individual subjects (rather than for
subpopulations) are of primary interest. It leads to smooth predicted survival curves and is well suited to deal with non-
proportionality of hazards. For instance, researchers increasingly often aim to develop prediction models that can assess
individual intervention benefits (or harms).90 Most simply, one can specify an exponential (eq. 1.2) or a Weibull (eq. 1.3) distri-
bution within the proportional hazards framework. The exponential distribution assumes a constant rate over time, whereas the
Weibull distribution (a generalization of the exponential distribution) allows for accelerated failure times (AFT).14 Other (but
less common) generalizations of the exponential distribution that can be used for modeling the baseline hazard are the Gompertz,
gamma, and piecewise constant distributions.14,83 Further, the log-logistic, log-normal and generalized gamma distributions may
be used.89,83 Unlike PH models, the estimate of an intervention effect in AFT models is unaffected by unmeasured prognostic
covariates.21 Also in one-stage models a wide range of distributions for parametric PH and AFT models is available.83
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5.2 Modeling non-proportional hazards
For short trials with a low event rate the proportionality of hazards across time may be reasonable (i.e. the hazard ratio for the
intervention effect may be assumed constant over time), but as the number of events in different intervention groups diverges a
selection of participants remains in the trial for whom proportionality in the unadjusted intervention effect is not realistic.91,92
If an intervention is protective, frail participants in the intervention group will be better protected against the outcome than frail
participants in the control group. Hence, the proportion of frail participants at risk will decrease more quickly in the control
group than in the intervention group. To account for this issue within studies we can include covariates in the model, whereas
we can use a frailty model to account for this issue between studies.
Non-proportionality of hazards may also be present due to the intervention effect truly being dependent on time. For instance,
an intervention (such as surgery or chemo-therapy) may cause an increased risk of a negative outcome at first, but have a
protective effect in the long run. This can be modeled by an interaction effect between the intervention (or a covariate) and time18
in the one-stage approach or in the first stage of the two-stage approach. To allow for flexible shapes of this time-dependent
effect, fractional polynomials or splines can be applied.93,94,95
Two methods have been developed for combining fractional polynomials or splines in the two-stage approach. The meta curve
method directly meta-analyzes the curves estimated in the first stage. Though, this requires setting a reference level which may
have an impact on the results. Alternatively, by using multivariate meta-analysis (section 5.3) the coefficients can be combined.
This method only works when the same polynomials or splines have been fitted in each study, but that is not an issue when IPD
are available.96
Alternatively, non-PH can sometimes be handled more naturally with models that assume proportionality on another scale.92,89
For instance, an intervention might temporarily reduce the hazards, but as time progresses and the effect wears off, hazards
converge and thereby violate the proportional hazards assumption. This can be modeled with a proportional odds regression
model such as the log-logistic (equation 1.7, Table 1), which assumes that covariates have a constant additive effect on the log
odds of survival.97,98,99,27 In this model, the modeled hazard ratio naturally approaches 1 over time, whereas the odds remain
proportional.98
As the implementation of TTE models with non-proportional hazards (e.g. with splines) may complicate the interpretation of
regression parameters, alternate effect measures have been proposed to summarize intervention effects (Table 7). For instance,
the restricted mean survival time (RMST, equation 7.3) until time 𝑡∗ represents the area under the survival curve until time
𝑡∗.100,101,102 The RMST can thus be calculated for different intervention groups, and subsequently be subtracted to assess the
intervention effect. This difference represents the expected gain (or loss) in survival until time 𝑡∗ for the intervention group, as
compared to the control group. An advantage is that it provides a clinically meaningful summary of the survival differences
between intervention groups.
The percentile ratio, an effect measure alternative to the more common hazard ratio, was suggested by to make the interpreta-
tion of survival models more straightforward.103 Briefly, the percentile ratio for an intervention is defined as the expected ratio
for the time at which a certain fraction (given as ’k’) of the participants will have an event in the intervention group as com-
pared to the control group (equation 7.4) . The percentile ratio is easiest to interpret for AFT models, as the percentile ratio does
not depend on the percentile chosen in such models and always equals the acceleration factor. Two-stage MA methods for the
percentile-ratio have also been developed.104
5.3 Modeling multiple outcomes
Throughout this manuscript, we have assumed that each patient in each trail is at risk of having a single type of event (i.e. the
outcome of interest, e.g. all-cause mortality), until censoring takes place. Alternatively, patients may be at risk for different
events, where one event (e.g. death) prevents the patient from having another event (e.g. liver failure or stroke). Unlike the
survival function, relative intervention effects can then still be assessed by modeling cause-specific hazards, which involves the
modeling of the time to each type of event in a separate model, where all alternative types of event are coded as censoring.105,106
It is vital to do this for every type of event, to gain a full understanding of the relative intervention effect with respect to competing
events.105 Whereas for all-cause-mortality there is a direct relation between the hazard and the survival curve, when modeling
cause-specific hazards this is not the case,107 meaning that this approach does not have a direct interpretation in terms of absolute
survival probabilities for the outcome of interest.108 Only when independence of the event of interest and the competing event
can be assumed, the survival function can be estimated by recoding the competing outcome as censoring, though this assumption
is often not realistic.109
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Therefore, when prediction of the average time-to-event per intervention group is wanted, competing events must be modeled
using more complex survival models (for an introduction see105,110). In the two-stage approach, this can be analyzed with
competing risk models in the first stage, whereas Bayesian hierarchical competing risk models have been developed for the one-
stage approach,111 which may also model recurrent events jointly with the competing risk.112 Further, multi-state models can
be used to model transitions to intermediate events.113
When multiple outcomes that do not compete are available across trials, these can be assessed jointly in the two-stage frame-
work to improve the efficiency of the analyses.114,115 For instance, outcomes may have been assessed at multiple follow-up times,
or be defined for multiple endpoints. In the first stage, estimates of the intervention effects and variances are obtained for each
outcome in each trial. Bootstrapping is used to obtain the covariance between intervention effects for each pair of outcomes in
the same trial.115 In the second stage, the vectors of estimates (and matrices of variances and covariances) are synthesised using
a multivariate meta-analysis model in the second stage. Hence, multivariate meta-analysis is particularly relevant to address
outcomes or time-points in the IPD from some trials.
5.4 Modeling multiple interventions
The concepts of multivariate meta-analysis can also be used to compare more than two interventions. In a so-called network meta-
analysis (NMA), direct and indirect evidence about the difference in effect of two or more treatments is combined across trials,
to summarize the relative effects of all available interventions. This may improve precision of the intervention estimates and
allows for comparison of interventions that have not been compared head-to-head. This method uses direct evidence (intervention
effects estimated within trials) and indirect evidence (intervention effects estimated across trials), by assuming that both sources
of evidence are exchangeable.116,117. When direct and indirect evidence disagree, the network is said to be inconsistent and may
be prone to bias or may cause heterogeneity of the estimated intervention effects. Such inconsistency can be caused by effect
modification, which can be addressed by modelling interactions between the intervention and patient-level covariates.118
In the two-stage approach, an appropriate (e.g. Cox) survival model is first estimated in each trial, possibly adjusting for
relevant prognostic factors and effect modifiers. Corresponding effect estimates (e.g.log hazard ratios) can then be pooled
using traditional NMA methods.116 In the one-stage approach, time-to-event NMA models can be estimated using Bayesian
hierarchical models.119,120 Also, Bayesian one-stage IPD-NMA Royston-Parmar models have been implemented.121
5.5 Surrogate endpoints
Trials for measuring intervention efficacy tend to be expensive and require a lengthy follow-up to observe the clinical outcome.
The cost and duration of a trial may be reduced if a more readily available outcome can be used. Validated surrogate endpoints
can be used instead when the surrogate is well known or likely to predict clinical outcome.122 These surrogate endpoints are to be
validated on the trial and the participant level, where IPD form multiple trials are preferred.123,124 When response to intervention
is used to predict survival, response must be modeled as a time-dependent covariate or a landmarking method must be used.125
Alternatively, a joint model with the survival outcome and a continuous surrogate or a dichotomous surrogate can be used.126,127
For an overview and comparison of the performance of measures of surrogacy, see128,129.When few trials are available, the trial
level surrogacy cannot reliably be estimated using AD alone. However, surrogacy can sometimes be estimated on the center level
by splitting multi-center data by center.124,130 This requires IPD when center specific parameter estimates are not available. For
a recent overview of methods for estimating surrogacy, see130. To include a surrogate directly in the modeling of the outcome,
a joint model can be used.126,127 For the one-stage approach, joint models with up to three levels have also been developed.131
5.6 Missing data
In a meta-analysis of survival data, several types of missing data may occur. It is possible, for instance, that not all studies provide
IPD and thus that only AD are available for some of the studies. In such cases, it is recommended to combine the available IPD
and AD, as otherwise estimated intervention effects may be prone to (data availability) bias and overly large standard errors.132
Including AD in a two-stage meta-analysis approach is fairly straightforward, provided that the model used for generating the
AD is compatible with the models for analyzing the available IPD. It is also possible to directly combine IPD and AD using a
one-stage meta-analysis, although this requires more advanced models, such as Bayesian hierarchical regression.133
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Another common type of missing data occurs when events of individual subjects are censored, e.g. due to loss of follow-up.
Survival models such as the Cox PH model and the AFT model readily account for this censoring, provided that it is not related
to the outcome, conditional on any participant-level characteristics in the model (i.e. non-informative). When the assumption of
independent censoring is challenged, its implications can be evaluated by adopting multiple imputation methods.134
Finally, it is possible that subject-level covariates are missing for one or more studies. Although participant covariates are
not commonly used when estimating relative intervention effects from RCTs, they are crucial in IPD-MA of time-to-event data
because of selection differences across trials (see section 2). When relevant participant-level covariates are missing for some
trial participants, it is generally recommended to apply multiple imputation.135 Hereby, researchers should adjust for the event
indicator and the Nelson-Aalen estimator of the cumulative hazard,136,137 and also account for the presence of clustering. The
latter can be achieved by adopting imputation models with mixed effects, which also facilitates imputation of covariates that
have not been measured in one or more studies.138,139,140,141,142
Although the assumptions needed for multiple imputation cannot always be tested or may not always be met, several simulation
studies have shown that its use is usually superior to complete-case analysis or the use of missing data indicators.143 However,
caution is still warranted when analyzing imputed data sets from IPD-MA, as in the presence of between-trial heterogeneity these
are inherently prone to some degree of incompatibility with the data generation mechanism.144,141 Further, because IPD-MA
can only adjust for measured covariates and may therefore still be affected by unmeasured covariates, clustering of participants
within trials should still be accounted for (section 4.3.1).14
6 APPLIED EXAMPLE
The efficacy of carbamazepine (CBZ) and valproate (VP) as interventions for epileptic seizures was compared in a systematic
review and IPD-MA of RCTs.145 IPD were obtained for a total of 1225 participants from five trials. In all these trials, one of the
outcomes of interest was time to first epileptic seizure since randomization. Also, measured covariates were age at randomiza-
tion, sex, type of epilepsy (partial-onset or generalized-onset), and the number of epileptic seizures before randomization. For
illustrative purposes, we only consider the type of epilepsy. We use the coxme package of the R software,146,147 to fit the mixed
effects Cox PH model. Our code is given in Supporting Information 2.
As the two-stage method has been described extensively (see104,148) we shall restrict our analyses to illustrate some key one-
stage methods. First, to evaluate the relative effects of CBZ and VP, we adopted a Cox model, as this leaves the baseline hazard
unspecified. We apply a one-stage model (eq. 5.2) with a log-normal frailty and random effects for the intervention estimated
with penalized partial likelihood to account for the clustering of participants within trials and to allow for heterogeneous inter-
vention effects across trials, respectively. We find no evidence against the hypothesis that the interventions are equally effective,
with a summary hazard ratio of 1.08 for valproate (95% Confidence Interval (CI): 0.92 to 1.27, p = .37), versus the referent,
carbamazepine.
In the analysis of the effect of the intervention on the time to first epileptic seizure, we observed some statistical heterogene-
ity of the intervention effect. The standard deviations of the random intercept (i.e. frailty) and drug effect (i.e. random effect)
equaled 0.139 and 0.099, respectively. In other words, the log hazard ratio of valproate versus carbamazapine varied with a
standard deviation of .099 between trials. This random effect of the interventions translated to a Median Hazard Ratio (MHR)
of 1.10, meaning that the median relative change in the effect on time-to first epileptic seizure when comparing two identi-
cal participants from two randomly selected different trials that were ordered by intervention effect was 1.10, calculated as
exp{
√
2 0.099 Φ−1(0.75)} (see section 4.3.6). In order to explain this heterogeneity in intervention effect, we added covariates
and intervention-covariate interactions to the model (Figure 2). Partial epilepsy (vs generalized) was associated with a higher
hazard rate (𝛽 = 1.63, 95% CI: 1.38 to 1.92, Table 8), meaning that we have found evidence that epilepsy type is a prognostic
factor of time to first epileptic seizure. However, we were unable to find evidence that epilepsy type interacted with the inter-
vention (𝛽 = 1.36, 95% CI: 0.97 to 1.89), though it should be noted that the upper bound of the CI did not exclude clinically
significant effects. We note that we obtained somewhat different results than the Cochrane review,149 as we have used a different
method for analysis. Further, the low power for tests for interaction effects is a notorious issue.
A recent investigation of the intervention-covariate interaction on the time to remission of epilepsy demonstrated that bias
occurs when within-trial and across-trial information is not separated.88 Such separation can be performed by centering the
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FIGURE 2 Kaplan-Meier plot of Generalized and Partial Epileptic Seizure Patients Treated with Carbamazapine (CBZ) or
Valproate (VP)
covariates, hence we have centered the covariates in in our analysis (Table 8). The possible bias that may occur when within-
trial and across-trial information are amalgamated can be quantified by including the trial-mean in the model,88 as we have done
here (Table 8).
7 DISCUSSION
Our search has identified a wide range of articles on topics regarding TTE IPD-MA, and is the first comprehensive review on
this topic to our knowledge. However, the basics of the methodology regarding TTE data was excluded from our search as it
did not concern MA or clustered data. Covering all methodological works regarding TTE data would have been an immense
task. As such, we were forced to include relevant literature based on our own opinion to introduce this topic, and restrict our
systematic search through Pubmed and Web of Science to works that simultaneously concerned IPD, meta-analysis and time-
to-event data. We did not cover every article that covers these three topics, as this was not our aim. Instead, we our purpose was
to achieve theoretical saturation, i.e. that an extended search would be unlikely to add important information.
The general consensus in the reviewed works was that the Cox model should be the default model of choice for TTE IPD-
MA. Though, it is also criticized for not yielding a valid estimate of intervention effect when not all (un-)measured predictive
covariates are accounted for, mostly on theoretical grounds. The literature is currently missing information on the impact of this
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issue in real life data, leading us to suggest that further research should focus thereon. As such, we have provided a comprehensive
review of current methods for IPD-MA of TTE data.
Although the statistical properties of the meta-analysis estimators for the two-stage approach have been well studied and
simulation studies have investigated the performance for meta-analysis of dichotomous and continuous outcome data, this is not
the case for time-to-event data. Further, although aggregate data (i.e. estimates from the literature) can readily be included in the
two-stage approach (provided that the models are specified the same), as well as in Bayesian one-stage models, there appears to
be no method yet for doing so in a Frequentist model.
Another issue is to what extend one should try to borrow information across trials in the one-approach. In the two-stage
approach, no information is borrowed (apart from the intervention effect and its uncertainty), as all parameters are naturally
estimated per trial. To what extend one should account for this in the one-stage approach, by stratifying the baseline and covariate
effects or by applying random effects and a frailty, deserves extra attention in the literature. For the meta-analysis of trials with
adequate sample sizes, the safest choice is to stratify all included parameters as this accounts for all differences in baselines
between trials. In a simulation study where IPD from a total of 600 participants from 3-20 trials were generated, both the frailty
and the stratified baseline method worked well,29 though exactly what sample sizes are necessary for this strategy, and especially
for the stratification of covariates as well, has apparently not yet been identified.
8 CONCLUDING REMARKS
We have discussed numerous models in this manuscript, the choice between which is not always straightforward. For this reason,
we provide some recommendations below. First, intervention effect conditional on covariates and/or frailties have different
interpretations from marginal ones (i.e. averaged over the entire sample and follow-up time), and yield different estimates. Before
embarking on an IPD-MA, researchers should decide whether a conditional or a marginal effect is of interest. As assumptions
may be satisfied on one scale but not the other, this may lead to a different choice of model.
Additionally, one can choose between one-stage and two-stage models. In the two-stage method participants within trials are
compared, which inherently yields a conditional intervention effect and stratified baselines. The one-stage approach offers more
possibilities as it allows for conditional intervention effects as well as marginal ones, and frailties for the baseline. When the
same (or similar) model assumptions are made for these models and the same estimation methods are used, these two approaches
generally lead to the same estimates of intervention effect.13,28 Though, the one-stage approach can have better convergence
properties when the included studies are very small,150,28 or at least one of the studies has zero events.
Further, when a conditional effect is desired (in contrast to a marginal one), we recommend to apply random effects instead of
common effects, as common effects models are only valid when no heterogeneity is present, which is unlikely in our experience.
When a marginal effect is desired, only a correction for the variance is necessary. As described in section 2, when an interven-
tion effect is present the estimated intervention effect in PH models may be time-dependent, depending on the distribution of
prognostic factors that are not accounted for (even if balanced across intervention groups). This may lead to heterogeneity in
intervention effects across trials that have different follow-up lengths. Further, differences in trial design and methodology and
clinical procedures may contribute to the heterogeneity of the intervention effect.12 Random effects models can account for het-
erogeneity of the intervention effect and lead to the same solution as common effect models when no heterogeneity is present.
However, if a formal test of heterogeneity is desired, a variety of tests can be used. For one-stage meta-analysis, the common
effect model (without trial effects) is nested in the frailty model, and therefore a comparison of these models can be made using
the log-likelihood ratio test.14 Alternatively, a score test,151,152,153 or a small sample test can be used.154 A permutation test for
testing of the presence of heterogeneity in time-to-event data was recently proposed, and a simulation showed that the method
is more powerful and has a better type I error rate than likelihood ratio tests of a random effect.155
Finally, when comparing non-nested (e.g. PH versus AFT) models, more general methods are needed. In such cases, one
may select the model with lowest value for Akaike’s Information Criterion (AIC)156,157 or the Bayesian Information Criterion
(BIC)158,156,157. Though, due to the correlated nature of participants within trials a correction for clustering should be made,
which is not straightforward in the frequentist estimation framework as quantification of the number of degrees of freedom is
difficult. For subject-specific inferences, the conditional (cAIC) can be used, whereas for inferences on the population level the
marginal AIC can be used.159,74,64,160
Further, one should be cautious regarding model selection. If one model is rejected, bias will appear in the estimated inter-
vention effect and significance in a second model if the second model is not independent of the test that was used to reject the
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first, such as when a non-PH effect is included in the model after a statistical test indicated non-proportionality.161 This bias
can be alleviated by bootstrapping the model selection procedure. On the other hand, this bias does not occur when the second
model is independent of the test used to reject the first model.161
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TABLES
TABLE 1 Models for two-stage time-to-event meta-analysis
Type Model Hazard function Survival function Ref. No.
Proportional
Hazards
General model1 ℎ0(𝑡) exp(𝜷′𝑿) 𝑆(𝑡|𝑿) = 𝑆0(𝑡)exp(𝜷′𝑿) 14,12,162 1.1
Exponential 𝜆 exp(𝜷′𝑿) 𝑆(𝑡|𝑿) = exp(−𝜆𝑡 exp(𝜷′𝑿)) 14,16,162 1.2
Weibull2 𝜆𝜈𝑡𝜈−1 exp(𝜷′𝑿) 𝑆(𝑡|𝑿) = exp(−𝜆𝑡𝜈 exp(𝜷′𝑿)) 14,163,16,162 1.3
Gompertz3 𝜆 exp(𝜓𝑡) exp(𝜷′𝑿) 𝑆(𝑡|𝑿) = exp(− 𝜆
𝜓
(exp(𝜓𝑡) − 1) exp(𝜷′𝑿)) 14,164,16 1.4
Accelerated
Failure Time
General model ℎ0(𝑡 exp{𝜷′𝑿}) exp(𝜷′𝑿) 𝑆(𝑡|𝑿) = 𝑆0(𝑡 exp(𝜷′𝑿)) 14,16,89 1.5




𝑆(𝑡|𝑿) = 𝜑𝑙𝑜𝑔(𝑡) + 𝜷′𝑿 89,98,99 1.7
1 In the Cox Proportional Hazards model, the baseline hazard ℎ0(𝑡) is left unspecified.
2 𝜈 is a shape parameter, 𝜆 is a scale parameter.
3 The Gompertz distribution can be generalized to the Gompertz-Makeham distribution by adding a constant to the hazard
function.165
4 The log-logistic model is a proportional odds model, where the 𝛽 parameters can be interpreted as log-odds ratios.
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TABLE 2 Ten Recommendations for the IPD-MA of TTE data from Randomized Trials Examining an Intervention Effect
Recommendation Reference
The Cox model may be the default model of choice, but proportionality of hazards 166,46
should be tested, e.g. with interaction or time-varying effects for the intervention.
Consider non-PH models. 167,92,168,89,121
Account for clustering in one-stage models, preferably by stratification of the baseline. 19,73,67,65,74,29
Adjust for covariates measured before randomization. 163,169,25
Apply one-stage models if trials are very small or the outcome very rare. 16,28
In one-stage models, center covariates within trials. 88
Model participant-level interactions on the participant-level. 45
For the intervention effect (& its interaction effects), apply random effects & investigate heterogeneity. 12,5,44,78
If competing risks are present & absolute risks are of interest, apply competing risks models. 108,105,170,109,111
Multiple imputation of missing covariates must account for clustering & time-to-event, 143,136,138,137,140
using the event indicator and the Nelson-Aalen cumulative hazard.
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TABLE 3 Methods for Modeling Heterogeneity
Baseline Coefficients Modeled difference between trials
Common Common No difference, same for every trial
Frailty Random Effects Proportional differences, difference between trials follows distribution
Fixed a Fixed b Proportional differences, estimated per trial. Same shape between trials.
Stratified Non-proportional differences. Estimated per trial, with different shapes.
These methods are possible in one-stage meta-analysis. In a two-stage meta-analysis the baseline is
stratified and the given options for the coefficients can be used.
a By adding trial indicators to the model.
b By adding trial indicators ∗ variable interaction to the model.
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TABLE 4 Potential sources of Heterogeneity in Time-to-event Meta-Analysis
Source Solutions Reference
Non PH + Differences in follow-up time Interaction terms 45,171,88
Model effect(s) as time-varying, use splines 91,83
Use a different model (e.g. AFT) 167,27,92,168,103,83
Difference in case-mix Include covariates / prognostic factors 36,163
AFT model 163,92,168
Selective dropout or competing risk Model dropout or competing risk 108,170,172,111
Small sample bias in some studies Bias correction 32
One-stage MA 173,172,7,28
Arcsine transform (for two-stage MA) 172
PH: Proportional Hazards; AFT: Accelerated Failure Time; MA: Meta-Analysis. Heterogeneity can be
diagnosed by applying frailty and/or random effects terms.29,78,13 If heterogeneity remains, e.g. due to dif-
ferences in study protocols, stratification of baseline hazard/frailty and/or random effects terms must be
applied.36,24
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TABLE 7 Effect Measures for Time-to-Event Analysis
Measure Definition Ref. No.
Hazard ratio 𝜆(𝑡|𝑿1)𝜆(𝑡|𝑿0) , 𝜆(𝑡|𝑿𝑘) = − 𝑑 ln(𝑆(𝑡|𝑿𝑘))𝑑𝑡 = 𝑓 (𝑡|𝑿𝑘)𝑆(𝑡|𝑿𝑘) 15,14 7.1
Odds ratio 𝑂(𝑡|𝑿1)𝑂(𝑡|𝑿0) , 𝑂(𝑡|𝑿𝑘) = 1−𝑆(𝑡|𝑿𝑘)𝑆(𝑡|𝑿𝑘) 27 7.2




𝑘th percentile of dist for group A
𝑘th percentile of dist for group B
103 7.4
RMST = Restricted Mean Survival Time, D = Difference.
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TABLE 8 Intervention, Covariates and Intervention-Covariate Interactions in a Multivariable Mixed Effects Cox Model
Variable Variable Type HR 95 % CI 𝑝
VP (vs CBZ) Intervention 1.05 0.86 to 1.28 0.65
Partial epilepsy (vs generalized), centereda Individual-level covariate 1.63 1.38 to 1.92 < .001
Partial epilepsy (vs generalized), trial meanb Trial-level covariate 1.47 0.99 to 2.19 0.06
Partial epilepsy (vs generalized), centereda* VP (vs CBZ) Intervention-covariate interaction 1.36 0.97 to 1.89 0.07
VP: Valproate, CBZ: Carbamazepine, HR: Hazard ratio, given by 𝑒𝑥𝑝(𝛽), CI: Confidence interval. Standard deviations of random
intercept (i.e. frailty) and random effect of VP (vs CBZ) equal 0.126 and 0.164, respectively. 𝑝-values are for Wald type tests of
the null hypothesis that the log HR equals zero.
a Covariates are centered within trials, to avoid ecological bias (see88).
b Trial mean value for the covariate is entered in the analysis, to quantify the bias that would occur if centering of the covariate
were not performed.
